HPC Biosciences Ltd Stock Price Today (NSE: HPBL)

HPC Biosciences Ltd

385.95+0.05 (+0.01%)
Market Closed

Fundamental Score

...

HPC Biosciences Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

HPC Biosciences Ltd share price today is 385.95, up +0.01% on NSE/BSE as of 22 September 2026. HPC Biosciences Ltd (HPBL) is a Small-cap company in the Packaging sector with a market capitalisation of 412.00 (Cr). The 52-week high for HPBL share price is 397.00 and the 52-week low is 140.10. At a P/E ratio of 18.52x, HPBL is currently trading below its industry average P/E of 21.40x. The company has a Return on Equity (ROE) of 24.37% and a debt-to-equity ratio of 3.00.

HPC Biosciences Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
385.95
Low
178.50
Volume
16.5K
Change
+71.58%

HPC Biosciences Ltd share price chart: 71.58% return over the past month. 52-week high ₹397.00, 52-week low ₹140.10.

HPC Biosciences Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
380.90397.00365.00385.9010.73K (Cr)
384.30384.30355.25383.8016.03K (Cr)
360.00366.00350.05366.005.90K (Cr)
349.05349.05335.00348.607.04K (Cr)
325.45332.45325.00332.457.84K (Cr)
316.45322.45295.00316.655.10K (Cr)
314.00318.00299.00309.956.42K (Cr)
310.85319.45300.00314.003.30K (Cr)
291.55319.00290.00306.1515.75K (Cr)
336.00336.45304.45305.2516.14K (Cr)

HPC Biosciences Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
276.95397.00270.40385.90+39.34%
183.00260.00175.00239.30+30.77%
200.05212.60171.55182.75-8.65%
251.50259.00196.00201.50-19.88%
267.00284.45230.00251.50-5.81%
158.10278.50158.00267.05+68.91%
180.10190.00158.00158.10-12.22%
153.15199.85142.30179.10+16.94%
170.00186.00140.10153.85-9.50%
200.95200.95156.10172.20-14.31%
155.05206.50150.00192.50+24.15%
160.15194.45150.00163.55+2.12%

Returns & Performance

Excellent

Return on Equity (ROE)

24.37%

Profit generated per ₹1 of shareholder equity

Excellent

Return on Capital (ROCE)

42.41%

Returns generated on total capital deployed

Poor

Oper. Profit Margin (5Y Avg)

7.28%

Average operating profit margin over 5 years

Dividend Yield

0.52%

Annual dividend as % of current share price

HPC Biosciences Ltd Valuation Check

Good

Price to Earnings (P/E)

18.52x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

21.40x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

75.00%

% shares held by company founders/management

Poor

FII Holding

4.50%

% shares held by foreign institutional investors

Poor

DII Holding

4.79%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Excellent

Profit Growth (Quarterly YoY)

124.51%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

-8.34%

Revenue growth vs same quarter last year

Excellent

Revenue Growth (5-Year CAGR)

105.91%

Compounded annual revenue growth over 5 years

Excellent

EPS Growth (5-Year CAGR)

27.13%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

16.67%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Poor

Debt to Equity Ratio

3.00x

Total debt ÷ equity. Below 0.5 = financially healthy

Good

Interest Coverage Ratio

2.95x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

-173.08 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

HPC Biosciences Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of HPBL across key market metrics for learning purposes.

Positive Indicators

8 factors identified

Strong Return on Equity (24.37%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Excellent ROCE Performance (42.41%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.

Robust Profit Growth (124.51%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture.

Consistent Growth Track Record (105.91% CAGR)

Observation: Strong 5-year sales compound annual growth rate.

Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.

Excellent EPS Growth (27.13% CAGR)

Observation: Outstanding 5-year earnings per share compound growth.

Analysis: EPS CAGR >15% indicates strong wealth creation potential.

Strong Profit Growth Track Record (16.67% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Balanced Promoter Holding (75.00%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

5 factors identified

High Price-to-Book Ratio (5.03x)

Observation: Trading at significant premium to book value.

Analysis: High P/B ratios may indicate overvaluation relative to asset base.

Revenue Contraction (-8.34%)

Observation: Sales decline may indicate market challenges or competitive pressures.

Analysis: Negative revenue growth requires analysis of market conditions.

Elevated Debt Levels (D/E: 3.00)

Observation: High leverage increases financial risk and interest burden.

Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.

Negative Free Cash Flow (₹-173.08 Cr over 5Y)

Observation: Cash outflows exceed inflows.

Analysis: Negative FCF requires analysis of capital expenditure cycle.

Limited Institutional Interest (FII+DII: 9.29%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

HPC Biosciences Ltd vs Packaging Peers

Peer Comparison - Packaging

Compare HPC Biosciences Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
63.7/100
386
₹412.00
18.5
Average
24.37%
Excellent
42.41%
Excellent
3.0
Poor
16.67%
Excellent
105.91%
Excellent
0.52%
39.4/100
247
₹7906.73
20.4
Average
14.92%
Average
18.63%
Good
0.2
Excellent
10.22%
Good
9.03%
Good
2.10%
67.2/100
796
₹5151.09
14.2
Average
0.00%
Poor
18.44%
Good
0.1
Excellent
32.37%
Excellent
7.55%
Good
1.01%
35/100
680
₹4911.36
7.2
Average
0.00%
Poor
8.49%
Poor
1.2
Average
-17.07%
Poor
11.61%
Good
0.68%
23.3/100
1140
₹3578.46
23.0
Average
1.12%
Poor
1.05%
Poor
0.2
Excellent
-38.52%
Poor
7.58%
Good
1.26%
50.1/100
3820
₹3475.93
30.1
Average
14.35%
Average
21.08%
Excellent
0.8
Good
23.91%
Excellent
15.35%
Excellent
0.76%
35.4/100
1301
₹3054.44
92.5
Average
2.81%
Poor
3.86%
Poor
0.4
Excellent
19.45%
Excellent
6.25%
Good
0.14%
13.2/100
676
₹2958.65
-29.57%
Poor
-15.41%
Poor
1.3
Average
-28.49%
Poor
-6.61%
Poor
0.87%
42.6/100
907
₹2380.22
14.1
Average
0.00%
Poor
11.33%
Average
1.0
Good
-7.12%
Poor
9.75%
Good
0.48%
38/100
690
₹2293.66
30.2
Average
10.98%
Average
14.81%
Average
0.3
Excellent
8.73%
Good
13.11%
Good
0.58%
31/100
268
₹2023.61
14.8
Average
9.50%
Poor
12.41%
Average
0.1
Excellent
4.24%
Average
0.05%
Average
0.90%

HPC Biosciences Ltd Quarterly Performance

Latest quarterly metrics for HPBL — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

-8.34%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

124.51%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

105.91%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

16.67%

Compounded annual net profit growth over 5 years

HPC Biosciences Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for HPBL — calculated from daily price history

73RSI 14
Overbought — RSI 73

Momentum is strong — price may be stretched. Watch for pullbacks.

SMA 50
215
▲ Price above SMA 50 — Short-term bullish
SMA 200
200
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
13K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

HPC Biosciences Ltd Financial Statements

Annual income statement, balance sheet and cash flow for HPC Biosciences Ltd (HPBL) — sourced from NSE/BSE filings.

Financial Results & Statements

Latest quarterly, annual and period-wise financial data for HPC Biosciences Ltd

Loading latest quarterly results...

About HPBL (HPC Biosciences Ltd)

HPC Biosciences Ltd is a pioneer in the design and manufacture of innovative packaging solutions tailored for the demanding needs of the biopharmaceutical industry. HPBL specialize...s in developing and producing high-performance containers and delivery systems, focusing on maintaining the integrity and efficacy of sensitive biological materials. Their product line encompasses a range of temperature-controlled packaging, including insulated shippers and phase change material (PCM) solutions, ensuring consistent and reliable temperature maintenance throughout the cold chain. Furthermore, HPBL is committed to sustainable practices, exploring biodegradable and recyclable materials to minimize environmental impact. They offer customized packaging solutions designed to meet specific product requirements, including various sizes, formats, and security features, guaranteeing product safety and security during transportation and storage. HPBL's core expertise lies in its ability to combine advanced materials science with precision engineering, producing packaging that exceeds industry standards. Their innovative approach includes integrating real-time monitoring capabilities, allowing for complete visibility of the package's environmental conditions throughout its journey. This integration of technology ensures that clients can track temperature, humidity, and other critical parameters, facilitating informed decision-making and mitigating potential risks. HPBL places a strong emphasis on research and development, consistently pushing the boundaries of packaging technology. They are dedicated to providing reliable and cost-effective solutions that address the evolving challenges faced by the biopharmaceutical sector. HPBL distinguishes itself through its commitment to quality and regulatory compliance, adhering to the most stringent global standards, including those set by the World Health Organization (WHO) and the International Safe Transit Association (ISTA). Their manufacturing processes are meticulously controlled, utilizing state-of-the-art equipment and employing rigorous quality assurance measures. HPBL works in close collaboration with its clients, providing technical support and expert guidance to ensure optimal packaging performance. This collaborative approach extends from initial design concepts to final product delivery, fostering long-term partnerships built on trust and mutual success. HPBL aspires to be the preeminent provider of packaging solutions, empowering the biopharmaceutical industry to deliver life-saving therapies worldwide.

Company Details

Symbol:HPBL
Industry:Packaging
Sector:Packaging

Key Leadership

Mr. Prakash Hiralal Parekh
MD & Executive Director
Jagdeep Singh Rana
Vice President
Mr. Dhrumil Pranavkumar Shah
Chief Financial Officer

HPBL Share Price: Frequently Asked Questions

What is the current share price of HPC Biosciences Ltd?

HPC Biosciences Ltd (HPBL) trades at ₹385.95 on NSE and BSE. Market cap ₹412.00 (Cr). Educational data only.

What is the P/E ratio of HPC Biosciences Ltd?

HPC Biosciences Ltd has a P/E of 18.52x vs industry average 21.40x.

What is the Bull Run score for HPC Biosciences Ltd?

HPC Biosciences Ltd has a Bull Run score of 63.7/100 based on 25+ financial parameters.

Does HPC Biosciences Ltd pay dividends?

HPC Biosciences Ltd has a dividend yield of 0.52%. Past dividends don't guarantee future payments.

What is the ROE of HPC Biosciences Ltd?

HPC Biosciences Ltd has ROE of 24.37%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of HPC Biosciences Ltd?

HPC Biosciences Ltd has debt-to-equity of 3.00.

Is HPC Biosciences Ltd a good investment?

Bull Run gives HPC Biosciences Ltd a score of 63.7/100. This is not investment advice — consult a SEBI-registered advisor.